CL2019003215A1 - Anticuerpos agonistas contra btla y sus usos. - Google Patents
Anticuerpos agonistas contra btla y sus usos.Info
- Publication number
- CL2019003215A1 CL2019003215A1 CL2019003215A CL2019003215A CL2019003215A1 CL 2019003215 A1 CL2019003215 A1 CL 2019003215A1 CL 2019003215 A CL2019003215 A CL 2019003215A CL 2019003215 A CL2019003215 A CL 2019003215A CL 2019003215 A1 CL2019003215 A1 CL 2019003215A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies against
- agonist antibodies
- btla
- against btla
- antibodies
- Prior art date
Links
- 101150025010 Btla gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 abstract 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE PROPORCIONAN ANTICUERPOS QUE SE FIJAN A BTLA, Y MÉTODOS PARA USARLOS, EN DONDE DICHOS ANTICUERPOS SON ÚTILES COMO AGENTES PARA TRATAR AFECCIONES ASOCIADAS A LA ENFERMEDAD AUTOINMUNITARIA, QUE INCLUYEN EL TRATAMIENTO DE LUPUS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508510P | 2017-05-19 | 2017-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003215A1 true CL2019003215A1 (es) | 2020-04-13 |
Family
ID=62245543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003215A CL2019003215A1 (es) | 2017-05-19 | 2019-11-08 | Anticuerpos agonistas contra btla y sus usos. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10604573B2 (es) |
| EP (1) | EP3625257A1 (es) |
| JP (2) | JP6790304B2 (es) |
| KR (3) | KR20210106033A (es) |
| CN (3) | CN117402244A (es) |
| AR (1) | AR111752A1 (es) |
| AU (2) | AU2018269585B2 (es) |
| BR (1) | BR112019021547A2 (es) |
| CA (2) | CA3064518A1 (es) |
| CL (1) | CL2019003215A1 (es) |
| CO (1) | CO2019012756A2 (es) |
| CR (1) | CR20190521A (es) |
| DO (1) | DOP2019000293A (es) |
| EA (1) | EA201992460A1 (es) |
| EC (1) | ECSP19082184A (es) |
| JO (1) | JOP20190261A1 (es) |
| MA (1) | MA49133A (es) |
| MX (1) | MX2019013604A (es) |
| MY (1) | MY197425A (es) |
| NZ (1) | NZ758360A (es) |
| PE (1) | PE20191843A1 (es) |
| PH (1) | PH12019502575A1 (es) |
| TW (4) | TW202334237A (es) |
| WO (1) | WO2018213113A1 (es) |
| ZA (1) | ZA201906954B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| JP2022552323A (ja) | 2019-10-15 | 2022-12-15 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株 |
| GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| JP2023546713A (ja) * | 2020-10-23 | 2023-11-07 | アナプティスバイオ インコーポレイティッド | Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 |
| WO2023143565A1 (en) * | 2022-01-29 | 2023-08-03 | Hifibio (Hk) Limited | Anti-btla antibodies and uses thereof in treating cancer |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546541B2 (en) | 2002-06-20 | 2013-10-01 | Washington University | Compositions and methods for modulating lymphocyte activity |
| CA2503125C (en) * | 2002-10-25 | 2013-04-30 | Hilary Clark | Novel composition and methods for the treatment of immune related diseases |
| EA200970477A1 (ru) * | 2006-11-15 | 2009-12-30 | Медарекс, Инк. | Человеческие моноклональные антитела к btla и способы применения |
| EA201270228A1 (ru) * | 2009-07-31 | 2012-09-28 | Медарекс, Инк. | Полноценные человеческие антитела к btla |
| US9533039B2 (en) * | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| WO2014018931A1 (en) * | 2012-07-26 | 2014-01-30 | The General Hospital Corporation | Methods and compositions for treating autoimmune disease |
| WO2014183885A1 (en) * | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
| WO2016176583A1 (en) * | 2015-04-29 | 2016-11-03 | Sanford-Burnham Medical Research Institute | Modulation of immune response using btla agonist antibodies |
| WO2017096017A1 (en) * | 2015-12-02 | 2017-06-08 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
-
2017
- 2017-06-16 JO JOP/2019/0261A patent/JOP20190261A1/ar unknown
-
2018
- 2018-05-03 AR ARP180101158A patent/AR111752A1/es unknown
- 2018-05-04 TW TW112116965A patent/TW202334237A/zh unknown
- 2018-05-04 TW TW108133289A patent/TWI747043B/zh active
- 2018-05-04 TW TW110141711A patent/TWI804044B/zh active
- 2018-05-04 TW TW107115166A patent/TWI677504B/zh active
- 2018-05-11 MX MX2019013604A patent/MX2019013604A/es unknown
- 2018-05-11 AU AU2018269585A patent/AU2018269585B2/en active Active
- 2018-05-11 EP EP18727622.5A patent/EP3625257A1/en active Pending
- 2018-05-11 CR CR20190521A patent/CR20190521A/es unknown
- 2018-05-11 CA CA3064518A patent/CA3064518A1/en active Pending
- 2018-05-11 MA MA049133A patent/MA49133A/fr unknown
- 2018-05-11 CN CN202311364321.5A patent/CN117402244A/zh active Pending
- 2018-05-11 NZ NZ758360A patent/NZ758360A/en unknown
- 2018-05-11 CN CN201880033180.XA patent/CN110621699B/zh active Active
- 2018-05-11 BR BR112019021547-6A patent/BR112019021547A2/pt unknown
- 2018-05-11 MY MYPI2019006702A patent/MY197425A/en unknown
- 2018-05-11 CA CA3184628A patent/CA3184628A1/en active Pending
- 2018-05-11 CN CN202311364322.XA patent/CN117402245A/zh active Pending
- 2018-05-11 JP JP2020511876A patent/JP6790304B2/ja active Active
- 2018-05-11 PE PE2019002417A patent/PE20191843A1/es unknown
- 2018-05-11 KR KR1020217026470A patent/KR20210106033A/ko not_active Application Discontinuation
- 2018-05-11 US US15/977,003 patent/US10604573B2/en active Active
- 2018-05-11 KR KR1020227039792A patent/KR20220158847A/ko not_active Application Discontinuation
- 2018-05-11 EA EA201992460A patent/EA201992460A1/ru unknown
- 2018-05-11 KR KR1020197033639A patent/KR102294051B1/ko active Application Filing
- 2018-05-11 WO PCT/US2018/032218 patent/WO2018213113A1/en active Application Filing
-
2019
- 2019-10-22 ZA ZA2019/06954A patent/ZA201906954B/en unknown
- 2019-11-08 CL CL2019003215A patent/CL2019003215A1/es unknown
- 2019-11-15 CO CONC2019/0012756A patent/CO2019012756A2/es unknown
- 2019-11-15 DO DO2019000293A patent/DOP2019000293A/es unknown
- 2019-11-18 EC ECSENADI201982184A patent/ECSP19082184A/es unknown
- 2019-11-18 PH PH12019502575A patent/PH12019502575A1/en unknown
-
2020
- 2020-02-17 US US16/792,396 patent/US11396545B2/en active Active
- 2020-11-04 JP JP2020184527A patent/JP7072622B2/ja active Active
-
2021
- 2021-12-02 AU AU2021277743A patent/AU2021277743A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003215A1 (es) | Anticuerpos agonistas contra btla y sus usos. | |
| CL2017000651A1 (es) | Anticuerpos anti-glucagón y sus usos | |
| CL2019001043A1 (es) | Anticuerpos anti-il-33 y usos de los mismos. | |
| CL2017003404A1 (es) | Compuestos antibacterianos | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| UY35417A (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| NI201700060A (es) | Agonistas parciales del receptor de insulina | |
| ECSP17070399A (es) | Anticuerpos contra icos | |
| SV2017005355A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| UY36179A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| ECSP17005276A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| BR112017013176A2 (pt) | receptores de antígenos quiméricos e métodos para usá-los | |
| ECSP19059553A (es) | Anticuerpos anti-tgf-beta y su uso | |
| CL2019002251A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. | |
| CL2017001135A1 (es) | Anticuerpos mejorados contra il-6 | |
| NI201800134A (es) | Anticuerpos antifactor de la coagulación xi | |
| AR106133A1 (es) | Métodos para el tratamiento de la epilepsia | |
| BR112019025372A2 (pt) | Suplemento de ração animal, composição de ração animal, usos de um suplemento, métodos para produzir um suplemento de ração animal e para produzir uma composição de ração animal | |
| CL2020000655A1 (es) | Tratamiento mejorado de dermatitis atópica con tradipitant. | |
| DOP2019000082A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| ECSP17039183A (es) | Agonistas parciales del receptor de insulina | |
| ES1179009Y (es) | Sujetador para el pene | |
| AR103227A1 (es) | Anticuerpos anti-csf1r para el tratamiento de svp | |
| AR098780A1 (es) | Proceso de obtención de micropartículas de quitosano | |
| AR095235A1 (es) | Anticuerpos dirigidos contra il-33 y sus usos |